PI3K信号通路过度激活对非霍奇金淋巴瘤患者预后的影响及其靶向药物疗效  

Effect of excessive activation of PI3K signaling pathway on the prognosis of patients with non-Hodgkin lymphoma and the efficacy of targeted drugs

作　　者：乔薇 宋腾[2] 陈馨蕊 王华庆[2] Qiao Wei;Song Teng;Chen Xinrui;Wang Huaqing(Graduate School of Tianjin Medical University,Tianjin 300070,China;Department of Medical Oncology,Tianjin Union Medical Center,Tianjin Cancer Research Institute of Traditional Chinese and Westen Medicine,Tianjin 300121,China)

机构地区：[1]天津医科大学研究生院,300070 [2]天津市人民医院肿瘤诊治中心,天津市中西医结合肿瘤研究所,300121

出　　处：《国际肿瘤学杂志》2021年第2期121-124,共4页Journal of International Oncology

摘　　要：磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)/雷帕霉素靶蛋白(mTOR)信号通路过度激活与恶性肿瘤的发生发展及临床预后密切相关,以该信号通路为靶点的治疗药物可以有效抑制肿瘤的进展。目前美国食品和药物监督管理局批准了3种药物(CAL-101、BAY80-6946、IPI-145)用于治疗复发和难治性惰性非霍奇金淋巴瘤,临床上显示出显著的疗效和可控的安全性。The over-activation of phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)/mechanistic target of rapamcyin(mTOR)pathway is closely related to the occurrence,development and clinical prognosis of malignant tumors.Taking this signal pathway as a target can effectively inhibit tumor progression.At present,the Food and Drug Administration of the United States has approved three drugs(CAL-101,BAY80-6946,IPI-145)for the treatment of recurrent and refractory indolent non-Hodgkin lymphoma,which demonstrates significant efficacy and a manageable safety profile.

关 键 词：淋巴瘤 磷酸酰肌醇类 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]